Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$47,515 Mln
Revenue (TTM)
$6,068 Mln
Net Profit (TTM)
$1,074 Mln
ROE
0.1 %
ROCE
9.9 %
P/E Ratio
45.2
P/B Ratio
4.8
Industry P/E
--
EV/EBITDA
31.5
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$17.8
EPS
$1.8
Face value
--
Shares outstanding
580,800,000
CFO
$10,283.70 Mln
EBITDA
$11,661.20 Mln
Net Profit
$9,517.50 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Edwards Lifesciences Corp (EW)
| -3.1 | 5.3 | -2.6 | 17.0 | 0.8 | 0.5 | 11.4 |
|
BSE Sensex
| -9.4 | -8.1 | -9.3 | 3.4 | 9.8 | 9.0 | 12.0 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Edwards Lifesciences Corp (EW)
| 15.2 | -2.9 | 2.2 | -42.4 | 42.0 | 17.3 | 52.3 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Edwards Lifesciences Corp (EW)
|
82.6 | 47,515.3 | 6,067.6 | 1,073.5 | 20.4 | 10.6 | 45.2 | 4.8 |
| 108.5 | 187,721.9 | 44,328.0 | 6,524.0 | 20.0 | 13.1 | 29 | 3.6 | |
| 158.1 | 57,735.4 | 21,923.0 | 1,757.0 | 12.0 | 6.9 | 26 | 1.8 | |
| 71.3 | 102,581.0 | 20,074.0 | 2,886.0 | 14.7 | 12.5 | 35.6 | 4.2 | |
| 191.5 | 132,461.4 | 24,568.0 | 3,614.0 | 18.3 | 7.1 | 37.2 | 2.9 | |
| 577.1 | 45,820.3 | 4,303.7 | 1,059.5 | 31.7 | 66.2 | 43.9 | 28.5 | |
| 477.7 | 167,678.3 | 10,064.7 | 2,856.0 | 29.3 | 16.7 | 59.8 | 9.5 | |
| 227.9 | 33,694.9 | 5,398.1 | 1,485.9 | 34.0 | 24.2 | 22.8 | 5.3 | |
| 345.8 | 128,878.1 | 25,116.0 | 3,246.0 | 17.9 | 15.1 | 40.1 | 5.8 | |
| 464.7 | 172,506.1 | 44,556.0 | 6,737.0 | 19.5 | 13.1 | 26.2 | 3.3 |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive... replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Read more
CEO & Director
Mr. Bernard J. Zovighian
CEO & Director
Mr. Bernard J. Zovighian
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Edwards Lifesciences Corp (EW) is $82.61 (NYSE) as of 18-Mar-2026 16:02 EDT. Edwards Lifesciences Corp (EW) has given a return of 0.77% in the last 3 years.
The P/E ratio of Edwards Lifesciences Corp (EW) is 45.20 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
46.20
|
4.80
|
|
2024
|
10.47
|
4.37
|
|
2023
|
33.00
|
6.96
|
|
2022
|
30.21
|
7.92
|
|
2021
|
54.47
|
14.03
|
The 52-week high and low of Edwards Lifesciences Corp (EW) are Rs 87.89 and Rs 65.94 as of 19-Mar-2026.
Edwards Lifesciences Corp (EW) has a market capitalisation of $ 47,515 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Edwards Lifesciences Corp (EW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.66
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.